Tesaro Inc.
This article was originally published in Start Up
Executive Summary
Just over a year old at the start of June 2011, Tesaro Inc. raised a Series B financing of $101 million. This largest biotech venture financing of the year has enabled the company to start building its oncology pipeline, starting with the December 2010 in-licensing of rolapitant, a Phase III-ready drug candidate for chemotherapy-induced nausea and vomiting.